Posted in:News Final Judgment Entered in Amgen v. Coherus Neulasta Litigation By Seth Cockrum April 26, 2018 Comments are off Last week, on April 18, 2018, Judge Stark in the District of Delaware entered the Final Judgment and Order dismissing the patent... Read more Tagged with: Amgen, BLA, BPCIA, Coherus, Neulasta®, pegfilgrastim http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:Legal Humira®’s Wall of Patents Continues to Come Under Attack By Caitlin M. Wilmot November 13, 2017 Comments are off On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),... Read more Tagged with: AbbVie, Amgen, Boehringer Ingelheim, Coherus, Humira®, IPR, Legal, PTAB, Samsung Bioepsis, Sandoz http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Boehringer Ingelheim Prevails in IPR Against AbbVie’s ’135 Humira Patent By C. Nichole Gifford July 17, 2017 Comments are off Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer Ingelheim”) have prevailed in two... Read more Tagged with: AbbVie, adalimumab, Amgen, Boehinger Ingleheim, Coherus, Humira®, Legal, News, PTAB http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Coherus Files Four IPR Petitions on Humira® Patent By C. Nichole Gifford February 1, 2017 Comments are off Coherus Biosciences, Inc. (“Coherus”) has filed four petitions with the Patent Trial and Appeal Board (“PTAB”) for inter partes... Read more Tagged with: adalimumab, Amgen, Coherus, Humira®, Invalidity, IPR, Legal, News, PTAB, USPTO, Validity http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus